Eric Lefkofsky is CEO and co-founder of Tempus, a leading technological operating system designed toohelp fight cancer. He is also the leading founder or co-founder of such companies as; Groupon, a global e-commerce marketplace, Echo Global Logistics, and Inner Workings. He has also founded Lightbank, Mediaocean, and also Uptake Technologies a leading predictive analytics platform that is used in some of the worlds largest industries.
Eric Lefkofsky graduated from the University of Michigan and obtained his Juris Doctor at the University of Michigan Law School. Lefkofsky is an adjunct professor at the University of Chicago and has authored a book entitled Accelerated Disruption.
He serves as a trustee of Lurie Children’s hospital of Chicago and is also chairman of the Board of Trustees of Chicago’s Steppenwolf Theatre Company. In 2006 Eric established the Lefkofsky Family Foundation with his wife Liz. The private charitable foundation was founded to advance high-impact initiatives to improve lives in the communities it serves.
His startup Tempus a Chicago based firm founded in 2015, announced Thursday that they would be partnering with the University of Chicago Medicine (UChicago). The purpose of this partnership is to provide molecular sequencing and analysis to be available to UChicago breast cancer specialists with the goal of making breast cancer treatments as individualized and suited to each individual patient. Breast Cancer is the highest occurring cancer with very little accessible data and learn more about Eric.
Tempus will analyze data to map out genomes from about a 1,000 patients to help predict patterns in breast cancer and obviously the correlation between the two. The data will be used as a tool for doctors to provide the most educated effective procedure to treat each individual patient. This tool will also give a better idea of how the patient will respond to their method of treatment. Dr. OlufunmilayoOlopade professor of medicine and human genetics and dean for global health at the University of Chicago says, “We are excited to partner with Tempus on this initiative and eager to support its efforts to build the largest clinically annotated molecular data set in breast cancer” and more information click here.